NCT06122649

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Apremilast 30 mg Twice Daily in Chinese Subjects With Moderate to Severe Plaque-type Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 203 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with placebo in Chinese participants with moderate to severe PsO

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	apremilast	Oral tablet
DRUG	Placebo	Oral tablet

Timeline

• Start date: 2023-11-27
• Primary completion: 2025-02-28
• Completion: 2025-12-05
• First posted: 2023-11-08
• Last updated: 2026-01-05

Locations

21 sites across 1 country: China

Regulatory

• FDA-regulated drug study